Lifitegrast
 | |
| Clinical data | |
|---|---|
| Trade names | Xiidra |
| AHFS/Drugs.com | xiidra |
| Routes of administration | Eye drops |
| ATC code |
|
| Legal status | |
| Legal status |
|
| Identifiers | |
| |
| Synonyms | SAR-1118 |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEBI | |
| ChEMBL | |
| Chemical and physical data | |
| Formula | C29H24Cl2N2O7S |
| Molar mass | 615.48 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Lifitegrast (trade name Xiidra) is an FDA approved drug indicated for the treatment of signs and symptoms of dry eye. keratoconjunctivitis sicca dry eye syndrome. It is an ophthalmic solution applied in the form of eye drops two times a day.[1]
Adverse effects
Common side effects in clinical trials were eye irritation, discomfort, blurred vision, and dysgeusia (a distortion of the sense of taste).[2]
Pharmacology
Mechanism of action
Lifitegrast inhibits an integrin, lymphocyte function-associated antigen 1 (LFA-1), from binding to intercellular adhesion molecule 1 (ICAM-1). This mechanism down-regulates inflammation mediated by T lymphocytes.[1][3]
History
Lifitegrast was initially designed and developed by SARcode Bioscience[4] which was acquired by Shire in 2013,[5] who submitted a new drug application to the US Food and Drug Administration (FDA) in March 2015. The FDA granted Shire a priority review a month later, and requested additional clinical data, which were supplied in January 2016. The drug was finally approved on 11 July 2016.[6][7]
See also
- Restasis (ciclosporin eye drops for keratoconjunctivitis sicca)
References
- 1 2 Tauber, J (December 2015). "Lifitegrast Ophthalmic Solution 5.0% versus Placebo for Treatment of Dry Eye Disease: Results of the Randomized Phase III OPUS-2 Study". Ophthalmology. 122 (12): 2423–31. PMID 26365210. doi:10.1016/j.ophtha.2015.08.001.
- ↑ Drugs.com: Patient in formation for xiidra.
- ↑ Murphy, C. J.; Bentley, E; Miller, P. E.; McIntyre, K; Leatherberry, G; Dubielzig, R; Giuliano, E; Moore, C. P.; Phillips, T. E.; Smith, P. B.; Prescott, E; Miller, J. M.; Thomas, P; Scagliotti, R; Esson, D; Gadek, T; O'Neill, C. A. (2011). "The Pharmacologic Assessment of A Novel Lymphocyte Function-Associated Antigen-1 Antagonist (SAR 1118) for the Treatment of Keratoconjunctivitis Sicca in Dogs". Investigative ophthalmology & visual science. 52 (6): 3174–80. PMID 21330663. doi:10.1167/iovs.09-5078.
- ↑ Semba, Charles; Gadek, Thomas (2016). "Development of lifitegrast: a novel T-cell inhibitor for the treatment of dry eye disease". Clinical Ophthalmology: 1083. doi:10.2147/OPTH.S110557.
- ↑ "Shire To Acquire Sarcode Bioscience, Expands Presence In Ophthalmology". 25 March 2013.
- ↑ "FDA Approves Shire's Xiidra". 11 July 2016.
- ↑ Drugs.com: Xiidra (lifitegrast) FDA Approval History